Skip to main content
SpringerLink
Log in

Exploiting BH3 Mimetics for Cancer Therapy

  • Chapter
  • First Online:
Mitochondria: The Anti- cancer Target for the Third Millennium

  • 1198 Accesses

Abstract

In apoptotic cells, the transcriptional induction or posttranslational activation of Bcl-2-homolgy domain-3 (BH3)-only proteins triggers the activation of the pro-apoptotic pore-forming proteins Bax and Bak. All members of this subgroup of the Bcl-2 family share a nine amino acid BH3-domain which binds to a hydrophobic groove of anti-apoptotic Bcl-2 family members that comprises residues of their BH1, BH2 and BH3 domains. These observations led to the development of BH3 mimetics, a class of small-molecule inhibitors targeting the BH3-binding domain of the pro-survival Bcl-2 family members, thereby facilitating/activating Bax/Bak-dependent apoptosis. In addition, BH3 mimetics can displace the pro-autophagic BH3only protein Beclin-1 from a complex with pro-survival Bcl-2 family members to induce autophagy. BH3 mimetics hold great promise for the treatment of cancer and currently, a large variety of natural and synthetic BH3 mimetics are characterized in preclinical studies and developed in clinical studies in an aim to exploit their therapeutic potential for the treatment of cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adams JM, Cory S (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26:1324–1337

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, Yuan J (1996) Human ICE/CED-3 protease nomenclature. Cell 87:171

    Article  CAS  PubMed  Google Scholar 

  • Arnold AA, Aboukameel A, Chen J, Yang D, Wang S, Al-Katib A, Mohammad RM (2008) Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model. Mol Cancer 7:20

    Article  PubMed Central  PubMed  Google Scholar 

  • Balakrishnan K, Wierda WG, Keating MJ, Gandhi V (2008) Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 112:1971–1980

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bodur C, Basaga H (2012) Bcl-2 inhibitors: emerging drugs in cancer therapy. Curr Med Chem 19:1804–1820

    Article  CAS  PubMed  Google Scholar 

  • Bonapace L, Bornhauser BC, Schmitz M, Cario G, Ziegler U, Niggli FK, Schafer BW, Schrappe M, Stanulla M, Bourquin JP (2010) Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest 120:1310–1323

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bouillet P, Strasser A (2002) BH3-only proteins – evolutionarily conserved proapoptotic Bcl-2 family members essential for initiating programmed cell death. J Cell Sci 115:1567–1574

    CAS  PubMed  Google Scholar 

  • Cao X, Rodarte C, Zhang L, Morgan CD, Littlejohn J, Smythe WR (2007) Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma. Cancer Biol Ther 6:246–252

    Article  CAS  PubMed  Google Scholar 

  • Chen J, Jin S, Abraham V, Huang X, Liu B, Mitten MJ, Nimmer P, Lin X, Smith M, Shen Y, Shoemaker AR, Tahir SK, Zhang H, Ackler SL, Rosenberg SH, Maecker H, Sampath D, Leverson JD, Tse C, Elmore SW (2012) The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther 10:2340–2349

    Article  Google Scholar 

  • Chonghaile TN, Letai A (2008) Mimicking the BH3 domain to kill cancer cells. Oncogene 27(Suppl 1):S149–S157

    Article  CAS  PubMed Central  Google Scholar 

  • Codogno P, Meijer AJ (2005) Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ 12(Suppl 2):1509–1518

    Article  CAS  PubMed  Google Scholar 

  • Cory S, Adams JM (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2:647–656

    Article  CAS  PubMed  Google Scholar 

  • Danial NN (2007) BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res 13:7254–7263

    Article  CAS  PubMed  Google Scholar 

  • Dash R, Azab B, Quinn BA, Shen X, Wang XY, Das SK, Rahmani M, Wei J, Hedvat M, Dent P, Dmitriev IP, Curiel DT, Grant S, Wu B, Stebbins JL, Pellecchia M, Reed JC, Sarkar D, Fisher PB (2011) Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci U S A 108:8785–8790

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gelinas C, Fan Y, Nelson DA, Jin S, White E (2006) Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10:51–64

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, Yuan J (2001) Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 3:173–182

    Article  CAS  PubMed  Google Scholar 

  • Degterev A, Boyce M, Yuan J (2003) A decade of caspases. Oncogene 22:8543–8567

    Article  CAS  PubMed  Google Scholar 

  • Edinger AL, Thompson CB (2004) Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 16:663–669

    Article  CAS  PubMed  Google Scholar 

  • Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411:342–348

    Article  CAS  PubMed  Google Scholar 

  • Fischer U, Janicke RU, Schulze-Osthoff K (2003) Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 10:76–100

    Article  CAS  PubMed  Google Scholar 

  • Fulda S, Debatin KM (2004) Targeting apoptosis pathways in cancer therapy. Curr Cancer Drug Targets 4:569–576

    Article  CAS  PubMed  Google Scholar 

  • Fulda S, Debatin KM (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25:4798–4811

    Article  CAS  PubMed  Google Scholar 

  • Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C, Kroemer G (2006) Mechanisms of cytochrome c release from mitochondria. Cell Death Differ 13:1423–1433

    Article  CAS  PubMed  Google Scholar 

  • Gozuacik D, Kimchi A (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23:2891–2906

    Article  CAS  PubMed  Google Scholar 

  • Gozuacik D, Kimchi A (2007) Autophagy and cell death. Curr Top Dev Biol 78:217–245

    Article  CAS  PubMed  Google Scholar 

  • Green DR (2006) At the gates of death. Cancer Cell 9:328–330

    Article  CAS  PubMed  Google Scholar 

  • Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

    Article  CAS  PubMed  Google Scholar 

  • He C, Klionsky DJ (2009) Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 43:67–93

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Heist RS, Fain J, Chinnasami B, Khan W, Molina JR, Sequist LV, Temel JS, Fidias P, Brainerd V, Leopold L, Lynch TJ (2010) Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol 5:1637–1643

    Article  PubMed  Google Scholar 

  • Hengartner MO (2000) The biochemistry of apoptosis. Nature 407:770–776

    Article  CAS  PubMed  Google Scholar 

  • Hermanson D, Addo SN, Bajer AA, Marchant JS, Das SG, Srinivasan B, Al-Mousa F, Michelangeli F, Thomas DD, Lebien TW, Xing C (2009) Dual mechanisms of sHA 14–1 in inducing cell death through endoplasmic reticulum and mitochondria. Mol Pharmacol 76:667–678

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hetschko H, Voss V, Senft C, Seifert V, Prehn JH, Kögel D (2008) BH3 mimetics reactivate autophagic cell death in anoxia-resistant malignant glioma cells. Neoplasia 10:873–885

    CAS  PubMed Central  PubMed  Google Scholar 

  • Huang DC, Strasser A (2000) BH3-Only proteins-essential initiators of apoptotic cell death. Cell 103:839–842

    Article  CAS  PubMed  Google Scholar 

  • Igney FH, Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2:277–288

    Article  CAS  PubMed  Google Scholar 

  • Kang MH, Reynolds CP (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15:1126–1132

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kimura S, Noda T, Yoshimori T (2007) Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 3:452–460

    CAS  PubMed  Google Scholar 

  • Ko CH, Shen SC, Yang LY, Lin CW, Chen YC (2007) Gossypol reduction of tumor growth through ROS-dependent mitochondria pathway in human colorectal carcinoma cells. Int J Cancer 121:1670–1679

    Article  CAS  PubMed  Google Scholar 

  • Kögel D, Fulda S, Mittelbronn M (2010) Therapeutic exploitation of apoptosis and autophagy for glioblastoma. Anticancer Agents Med Chem 10:438–449

    Article  PubMed  Google Scholar 

  • Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreeff M (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:375–388

    Article  CAS  PubMed  Google Scholar 

  • Kroemer G, Galluzzi L, Brenner C (2007) Mitochondrial membrane permeabilization in cell death. Physiol Rev 87:99–163

    Article  CAS  PubMed  Google Scholar 

  • Lei X, Chen Y, Du G, Yu W, Wang X, Qu H, Xia B, He H, Mao J, Zong W, Liao X, Mehrpour M, Hao X, Chen Q (2006) Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2. FASEB J 20:2147–2149

    Article  CAS  PubMed  Google Scholar 

  • Lessene G, Czabotar PE, Colman PM (2008) BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 7:989–1000

    Article  CAS  PubMed  Google Scholar 

  • Lian J, Wu X, He F, Karnak D, Tang W, Meng Y, Xiang D, Ji M, Lawrence TS, Xu L (2010) A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell Death Differ 18:60–71

    Article  PubMed Central  PubMed  Google Scholar 

  • Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B (2009) An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 15:3172–3176

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Lowe SW, Lin AW (2000) Apoptosis in cancer. Carcinogenesis 21:485–495

    Article  CAS  PubMed  Google Scholar 

  • Maiuri MC, Le Toumelin G, Criollo A, Rain JC, Gautier F, Juin P, Tasdemir E, Pierron G, Troulinaki K, Tavernarakis N, Hickman JA, Geneste O, Kroemer G (2007) Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J 26:2527–2539

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Malik SA, Orhon I, Morselli E, Criollo A, Shen S, Marino G, BenYounes A, Benit P, Rustin P, Maiuri MC, Kroemer G (2011) BH3 mimetics activate multiple pro-autophagic pathways. Oncogene 30:3918–3929

    Article  CAS  PubMed  Google Scholar 

  • Manero F, Gautier F, Gallenne T, Cauquil N, Gree D, Cartron PF, Geneste O, Gree R, Vallette FM, Juin P (2006) The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res 66:2757–2764

    Article  CAS  PubMed  Google Scholar 

  • Martinou JC, Green DR (2001) Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2:63–67

    Article  CAS  PubMed  Google Scholar 

  • Meng Y, Tang W, Dai Y, Wu X, Liu M, Ji Q, Ji M, Pienta K, Lawrence T, Xu L (2008) Natural BH3 mimetic (−)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 7:2192–2202

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Milanesi E, Costantini P, Gambalunga A, Colonna R, Petronilli V, Cabrelle A, Semenzato G, Cesura AM, Pinard E, Bernardi P (2006) The mitochondrial effects of small organic ligands of BCL-2: sensitization of BCL-2-overexpressing cells to apoptosis by a pyrimidine-2,4,6-trione derivative. J Biol Chem 281:10066–10072

    Article  CAS  PubMed  Google Scholar 

  • Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, Nikolovska-Coleska Z, Wang S, Al-Katib A (2007) Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res 13:2226–2235

    Article  CAS  PubMed  Google Scholar 

  • Nicholson DW (1999) Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 6:1028–1042

    Article  CAS  PubMed  Google Scholar 

  • Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677–681

    Article  CAS  PubMed  Google Scholar 

  • Paoluzzi L, Gonen M, Gardner JR, Mastrella J, Yang D, Holmlund J, Sorensen M, Leopold L, Manova K, Marcucci G, Heaney ML, O’Connor OA (2008) Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 111:5350–5358

    Article  CAS  PubMed  Google Scholar 

  • Pattingre S, Levine B (2006) Bcl-2 inhibition of autophagy: a new route to cancer? Cancer Res 66:2885–2888

    Article  CAS  PubMed  Google Scholar 

  • Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B (2005) Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122:927–939

    Article  CAS  PubMed  Google Scholar 

  • Puthalakath H, Strasser A (2002) Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 9:505–512

    Article  CAS  PubMed  Google Scholar 

  • Ranger AM, Malynn BA, Korsmeyer SJ (2001) Mouse models of cell death. Nat Genet 28:113–118

    Article  CAS  PubMed  Google Scholar 

  • Ready N, Karaseva NA, Orlov SV, Luft AV, Popovych O, Holmlund JT, Wood BA, Leopold L (2011) Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. J Thorac Oncol 6:781–785

    Article  PubMed  Google Scholar 

  • Real PJ, Cao Y, Wang R, Nikolovska-Coleska Z, Sanz-Ortiz J, Wang S, Fernandez-Luna JL (2004) Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. Cancer Res 64:7947–7953

    Article  CAS  PubMed  Google Scholar 

  • Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R (2012) Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30:488–496

    Article  CAS  PubMed  Google Scholar 

  • Shoemaker AR, Oleksijew A, Bauch J, Belli BA, Borre T, Bruncko M, Deckwirth T, Frost DJ, Jarvis K, Joseph MK, Marsh K, McClellan W, Nellans H, Ng S, Nimmer P, O’Connor JM, Oltersdorf T, Qing W, Shen W, Stavropoulos J, Tahir SK, Wang B, Warner R, Zhang H, Fesik SW, Rosenberg SH, Elmore SW (2006) A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 66:8731–8739

    Article  CAS  PubMed  Google Scholar 

  • Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D, Oleksijew A, O'Connor JM, Wang B, Frost DJ, Bauch J, Marsh K, Tahir SK, Yang X, Tse C, Fesik SW, Rosenberg SH, Elmore SW (2008) Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 14:3268–3277

    Article  CAS  PubMed  Google Scholar 

  • Shore GC, Viallet J (2005) Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematol Am Soc Hematol Educ Program 2005:226–230

    Article  Google Scholar 

  • Sinicrope FA, Penington RC, Tang XM (2004) Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14–1, in human colon cancer cells. Clin Cancer Res 10:8284–8292

    Article  CAS  PubMed  Google Scholar 

  • Smoot RL, Blechacz BR, Werneburg NW, Bronk SF, Sinicrope FA, Sirica AE, Gores GJ (2010) A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res 70:1960–1969

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Strappazzon F, Vietri-Rudan M, Campello S, Nazio F, Florenzano F, Fimia GM, Piacentini M, Levine B, Cecconi F (2011) Mitochondrial BCL-2 inhibits AMBRA1-induced autophagy. EMBO J 30:1195–1208

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Tang G, Nikolovska-Coleska Z, Qiu S, Yang CY, Guo J, Wang S (2008) Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins. J Med Chem 51:717–720

    Article  CAS  PubMed  Google Scholar 

  • Tian D, Das SG, Doshi JM, Peng J, Lin J, Xing C (2008) sHA 14–1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell. Cancer Lett 259:198–208

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68:3421–3428

    Article  CAS  PubMed  Google Scholar 

  • Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmerberg J, Zhang KY, Hockenbery DM (2001) Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 3:183–191

    Article  CAS  PubMed  Google Scholar 

  • van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DC (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389–399

    Article  PubMed Central  PubMed  Google Scholar 

  • Vogler M (2012) BCL2A1: the underdog in the BCL2 family. Cell Death Differ 19:67–74

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Vogler M, Dinsdale D, Dyer MJ, Cohen GM (2009a) Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 16:360–367

    Article  CAS  PubMed  Google Scholar 

  • Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ, Cohen GM (2009b) Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 16:1030–1039

    Article  CAS  PubMed  Google Scholar 

  • Voss V, Senft C, Lang V, Ronellenfitsch MW, Steinbach JP, Seifert V, Kögel D (2010) The pan-bcl-2 inhibitor (−)-gossypol triggers autophagic cell death in malignant glioma. Mol Cancer Res 8:1002–1016

    Article  CAS  PubMed  Google Scholar 

  • Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, Huang Z (2000) Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A 97:7124–7129

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Wang G, Nikolovska-Coleska Z, Yang CY, Wang R, Tang G, Guo J, Shangary S, Qiu S, Gao W, Yang D, Meagher J, Stuckey J, Krajewski K, Jiang S, Roller PP, Abaan HO, Tomita Y, Wang S (2006) Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 49:6139–6142

    Article  CAS  PubMed  Google Scholar 

  • Wang Z, Song W, Aboukameel A, Mohammad M, Wang G, Banerjee S, Kong D, Wang S, Sarkar FH, Mohammad RM (2008) TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int J Cancer 123:958–966

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Wei J, Stebbins JL, Kitada S, Dash R, Placzek W, Rega MF, Wu B, Cellitti J, Zhai D, Yang L, Dahl R, Fisher PB, Reed JC, Pellecchia M (2010) BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 53:4166–4176

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Wendt MD, Shen W, Kunzer A, McClellan WJ, Bruncko M, Oost TK, Ding H, Joseph MK, Zhang H, Nimmer PM, Ng SC, Shoemaker AR, Petros AM, Oleksijew A, Marsh K, Bauch J, Oltersdorf T, Belli BA, Martineau D, Fesik SW, Rosenberg SH, Elmore SW (2006) Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J Med Chem 49:1165–1181

    Article  CAS  PubMed  Google Scholar 

  • Weyland M, Manero F, Paillard A, Gree D, Viault G, Jarnet D, Menei P, Juin P, Chourpa I, Benoit JP, Grée R, Garcion E (2011) Mitochondrial targeting by use of lipid nanocapsules loaded with SV30, an analogue of the small-molecule Bcl-2 inhibitor HA14-1. J Control Release 151:74–82

    Article  CAS  PubMed  Google Scholar 

  • Wolter KG, Wang SJ, Henson BS, Wang S, Griffith KA, Kumar B, Chen J, Carey TE, Bradford CR, D’Silva NJ (2006) (−)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia 8:163–172

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Zeitlin BD, Joo E, Dong Z, Warner K, Wang G, Nikolovska-Coleska Z, Wang S, Nor JE (2006) Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res 66:8698–8706

    Article  CAS  PubMed  Google Scholar 

  • Zhai D, Jin C, Satterthwait AC, Reed JC (2006) Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 13:1419–1421

    Article  CAS  PubMed  Google Scholar 

  • Zhang Z, Song T, Zhang T, Gao J, Wu G, An L, Du G (2011) A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1. Int J Cancer 128:1724–1735

    Article  CAS  PubMed  Google Scholar 

  • Zimmermann AK, Loucks FA, Schroeder EK, Bouchard RJ, Tyler KL, Linseman DA (2007) Glutathione binding to the Bcl-2 homology-3 domain groove: a molecular basis for Bcl-2 antioxidant function at mitochondria. J Biol Chem 282:29296–29304

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Experimental Neurosurgery, Center for Neurology and Neurosurgery, Neuroscience Center, Goethe University Hospital, Theodor-Stern-Kai 7, D-60590, Frankfurt am Main, Germany

    Donat Kögel

Authors
  1. Donat Kögel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donat Kögel .

Editor information

Editors and Affiliations

  1. School of Medical Science, Griffith University, Southport, Queensland, Australia

    Jiri Neuzil

  2. School of Medicine, National University of Singapore, Singapore, Singapore

    Shazib Pervaiz

  3. Institute for Experimental Cancer Research in Pediatrics, Goethe University, Frankfurt, Germany

    Simone Fulda

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Kögel, D. (2014). Exploiting BH3 Mimetics for Cancer Therapy. In: Neuzil, J., Pervaiz, S., Fulda, S. (eds) Mitochondria: The Anti- cancer Target for the Third Millennium. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-8984-4_2

Download citation

Publish with us

Policies and ethics

Search

Navigation